Subscribe to Search results

A report, "Prophylaxis in Haemophilia: A Double-blind Controlled Trial", was published in the British Journal of Haematology, recording the results of a trial of prophylactic Factor 8 treatment which was carried out at the Lord Mayor Treloar College.

Published on:

At a meeting of Haemophilia Centre Directors it was agreed that a controlled trial of prophylactic Factor 8 therapy would be useful.

Published on:

The UKHCDO discussed the proposal for a prophylaxis trial. Conducting such a trial was seen as problematic and Dr Biggs stated that the only place where it could be carried out in the UK was the Lord Mayor Treloar College.

Published on:

At a UKHCDO meeting a potential trial of prophylactic treatment was discussed and it was stated that they would only be able to undertake the trial at the Lord Mayor Treloar College.

Published on:

It was suggested that trials were possible at Treloar's due to the fact that the boys were under close daily observation for prolonged periods.

Published on:

The protocol for the Double-blind Controlled Trial of Prophylactic treatment at Treloars stated that half the children would only get a low dose in order for the trial to be effective.

Published on:

A proposal was submitted for a trial of prophylactic administration of cryoprecipitate at Treloars.

Published on:

Dr Aronstam sought a clinical trial exemption certificate to permit him to administer Mono-V3:C, a product of Speywood Laboratories, to 50 pupils over a period of 8 months.

Published on:

The Committee on Safety of Medicines advised that the bulk cryoprecipitate was to be prepared by Alpha Therapeutic only from source plasma derived from their own licensed plasmapheresis centres. This was considered to be risky as the effects resulting from these products were uncertain.

Published on:

Due to a large research grant Treloar's was able to supply students with much more blood product than their home clinicians.

Published on:

At a time of growing concerns about concentrates manufactured in the USA from large pools, no cryoprecipitate was used at Treloar's in 1982.

Published on:

At a time of growing concerns about concentrates manufactured in the USA from large pools, no cryoprecipitate was used at Treloar's in 1983.

Published on:

Conversation between Dr Aronstam, Adrian Goodyear and some boys of Treloar's where Dr Aronstam expressed his concern and emotions regarding the boys having been infected with HIV.

Published on:

Dr Aronstam told Adrian Goodyear, who attended Treloar's, that he had contracted HIV.

Published on:

Adrian Goodyear, a boy from Treloar's, stated Dr Aronstam's guilt towards the boys having contracted HIV and that the PHLS let him down by setting him up.

Published on:

At Treloar's NHS Concentrate was used a lot less compared to commercial concentrates.

Published on:

Richard Warwick, a student at Treloar's, stated that "they were crazy about prophylactics at Treloars' and prophylaxis was used 'like every day'.

Published on:

Treloar's were able to arrange to keep a pupil on one type of treatment for the 1975 hepatitis study.

Published on:

It was acknowledged there was a risk that the hepatitis might be Hepatitis B, even though screening had improved since RIA testing.

Published on:

It was stated that there were a variety of responses to exposure to hepatitis B virus in human beings: acute hepatitis, asymptomatic infection with little or no liver damage, chronic hepatitis, persistent production of hepatitis B viral antigen and antibody to surface antigens.

Published on: